September 21-23, 2010 • New York City

Save the date in your Microsoft Outlook Calendar

Individual Registration Group Registration 2010 Hotel Information 2010 Schedule Early Bird Registration Extended: Save $200 when you register by September 8, 2010 Cancellation Policy Conference Sponsorship Brochure 2009 Attending Companies 2009 Schedule

Interested in presenting at a Windhover conference? Submit your idea here

WHY ATTEND PSA?

Simple. Meet the most important people in the business.

The BIGGEST Names are Sending their Leadership Teams to PSA. And the hotel WILL sell out soon. Unprecedented networking. Abbott Allergan Inc. AstraZeneca Bayer Healthcare Bristol-Myers Squibb Company Celgene Corporation Chugai Pharmaceutical Co. Eli Lilly & Company Genentech Genzyme GlaxoSmithKline H. Lundbeck A/S Hoffmann-La Roche Merck and Company Pfizer Inc Purdue Pharma L.P. Sanofi-Aventis UCB Pharma SA Attend the ONLY strategic-level conference that delivers 100% case studies by the most important people in the business.

Benchmark your corporate strategies against the best and the brightest.

Featuring special guest speaker Mark McClellan on Pharma R&D: The New Customers Revaluing Its Output and Determining Its Direction  Mark McClellan, the most creative administrator the FDA and CMS have ever had (indeed, the only person to ever serve at the top of both agencies), and who is now the force behind some of the most innovative changes in payer and customer buying behavior, addresses the future of pharma R & D models. Mark McClellan, MD Former Administrator Medicare Medicaid Director, Engelberg Center for Health Care Reform The Brookings Institution

Featuring the workshop More Ways to Win: The Outlook for Pharma in 2020 In this workshop, Robin Arnold, vice president of IMS Health's Product and Portfolio Strategy practice, will reveal insights from the company's recent global study of pharmaceutical market growth opportunities over the next decade. The study uncovers new insights about the most promising areas for long-term investment and de-prioritization, the potential of R&D pipelines, emerging therapy approaches and the impact of early patient intervention on growth, along with raising important questions about how pharmaceutical companies can better prepare for a more promising, but uncertain future. Robin Arnold Vice President IMS Health

Additional featured speakers include: Roger Longman former Managing Partner Windhover Information Shaun Grady Vice President, Strategic Partnering and Corporate Business Development AstraZeneca Plc David Donabedian, PhD, M.B.A. VP Strategic Alliances, US Centre of Excellence for External Drug Discovery GlaxoSmithKline Gino Santini Senior Vice President, Corporate Strategy Eli Lilly and Company Robert S. Epstein, MD, MS Chief Medical Officer & President, Medco Research Institute Medco Health Solutions, Inc. Andrew Curtis Head of Biosimilars and Orphan Drugs Pfizer Rich Tillyer Senior Vice President, Worldwide Preclinical Development Merck & Company Michael Kamarck President, Merck BioVentures Senior Vice President Vaccines and Biologics Manufacturing Merck & Company James Sabry, MD, PhD Vice President of Partnering Genentech George Golumbeski SVP Business Development Celgene Dr. Stefan J. Oschmann President, Emerging Markets Merck & Company Jean Michel Halfon President and General Manager, Emerging Markets Business Unit Pfizer

After the Patent Cliff: Shared Risk For Shared Reward

The biopharma landscape of 2010 is dramatically different than one year ago but no less complex. Almost universally, the au courant phrase is shared risk for shared reward. The shift in mindset driving this thinking is subtle; to succeed, it implies if not an explicit partnership then an implicit compromise between parties such as small biotech and big pharma, and drug developer and payor. The ramifications of this shift, which will encompass every player in the biopharma drug development ecosystem, are already influencing dealmaking decisions.

At this year’s Pharmaceutical Strategic Alliances conference, we’ll gather some of the industry’s newest faces to enlighten us all on the concept of risk-sharing in its various facets:

Option-based deals, while not new, came into their own in 2009 and continue to be a force in 2010. VCs may increasingly look to risk-sharing alliances or options-to-acquire as a means to hedge the development costs of their portfolio companies, building their start-ups for this eventuality. Pharmas, eager to shed unnecessary infrastructure, will continue to push for alliances, or partial ownership structures where appropriate. They must also determine the best way to work with payors, especially in the US market.

Almost certainly the risk-sharing deals of tomorrow will be as varied as their developers, with an emphasis on bespoke arrangements that mirror the tailoring of medicines to individual patients. Join us this September at Pharmaceutical Strategic Alliances conference, where we’ll gather some of the industry’s newest faces to examine the concept of risk-sharing in its various facets.

Why attend PSA?

Maximize your strategic alliance opportunities by hearing CEOs, Senior R&D and Senior Business Development executives who share lessons learned, practical advice and strategies on how to build your R&D pipeline--both internally and externally.

And this September, PSA offers you an unbeatable line-up of Big Pharma and biotech speakers to forecast trends and analyze changes in alliances and M&A. You’ll hear from, and be able to quiz, top industry executives and dealmakers.

PSA gathers top thinkers to grapple with the fundamental challenges facing biotech and pharma – equipping dealmakers like you with the insights, information and practical advice you'll need to strike successful deals. This program will sell out so register early. Space is limited, so register today!

Top dealmakers around the industry are talking about Pharmaceutical Strategic Alliances...

“PSA’s 20th anniversary demonstrates the ongoing value of our powerful content, deep insight and expert analysis, year after year.” Roger Longman “Great meeting. Venue and meeting size were conducive to great access and networking.” Mohan Chukkapalli, Director, Business Development, Novo Nordisk Inc. “A great forum to interact with leading people from across the pharma industry.” Troy Harmon, VP, Business Development, Eurand “Topics and speakers excellent as usual. I travel to NYC each year to keep up to date on Pharma trends and paradigm shifts.” Audrey Erbes, Ph.D., Principal, Erbes & Associates

See you at the Millennium Broadway, New York City, this Sept. 21-23!

Cancellation Policy: The last day to cancel your registration for a refund, minus a $300 processing fee, is August 21. After that, you may send another delegate from your company.

Sponsors

Global Sponsors
Gold Industry Sponsors Silver Industry Sponsors Workshop Sponsors	Major Supporting Publications Media Partners Regional Supporting Organization Networking Break Sponsor